Manila Times Business
Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia
Optimi’s 5mg psilocybin capsules are prescribed commercially for treatment-resistant depression in Australia, with additional product from the run earmarked for planned clinical trials in the United States and Europe VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- via IBN - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of a
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Diamond drilling program under way at Leviathan Metals’ Central Project, Kalahari Copper Belt, Botswana
2h ago
Quoin Pharmaceuticals Submits IND Application for QRX003 in Peeling Skin Syndrome
2h ago
Paychex Small Business Jobs Index Improves for a Third Consecutive Month
2h ago
Safe Pro Awarded U.S. Army Order For AI-Powered Threat Analysis Kit Together with Red Cat Black Widow Drones
2h ago